This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
CONMED (CNMD) Q2 Earnings Beat, Sales Rise Y/Y, '24 View Cut
by Zacks Equity Research
CONMED (CNMD) beats second-quarter earnings estimates on the back of higher revenues and lower costs and expenses. However, the result reflects the continued impact of supply chain issues.
4 Stocks Trading Near 52-Week High That Can Climb Further
by Vasundhara Sawalka
Investors target stocks that have been on a bullish run lately. Stocks like UHS, THC, CCS and MGNI that are seeing price strength have a high chance of carrying the momentum forward.
Glaukos (GKOS) Q2 Earnings In Line, Glaucoma Drives Sales
by Zacks Equity Research
Glaukos' (GKOS) second-quarter 2024 results showcase growth in revenues on the back of strong adoption of its glaucoma products like iStent and iDose TR. Loss at the operating level raises concern.
Cencora (COR) Q3 Earnings Beat Estimates, '24 View Raised
by Zacks Equity Research
Cencora's (COR) third-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.
Humana (HUM) Q2 Earnings Beat on Medicare Advantage Strength
by Zacks Equity Research
Humana's (HUM) second-quarter results reflect overall premium growth and a well-performing CenterWell unit, partly offset by elevated costs. It expects individual MA membership to record growth of 225,000 in 2024.
Inari Medical (NARI) Q2 Earnings Miss, Revenues Increase Y/Y
by Zacks Equity Research
Inari Medical's (NARI) second-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the company continues to incur operating losses.
GE HealthCare (GEHC) Q2 Earnings Beat Estimates, Net Margin Up
by Zacks Equity Research
GE HealthCare's (GEHC) second-quarter results witness declining segmental revenues in imaging, ultrasound and patient care. The bottom line improves on better pricing.
Stryker's (SYK) Q2 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Stryker (SYK) beats second-quarter earnings estimates, driven by robust sales growth and innovative launches like the LIFEPAK 35 and Spine Guidance 5. The company raises 2024 guidance.
DENTSPLY SIRONA (XRAY) Q2 Earnings Miss, Revenues Decline Y/Y
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) second-quarter 2024 results showcase a year-over-year decline in earnings as well as sales.
Zacks.com featured highlights Hilton Grand Vacations, Tenet Healthcare, Universal Health, Popular and B2Gold
by Zacks Equity Research
Hilton Grand Vacations, Tenet Healthcare, Universal Health, Popular and B2Gold have been highlighted in this Screen of The Week article.
Fresenius Medical (FMS) Q2 Earnings In Line, Operating Margin Up
by Zacks Equity Research
Fresenius Medical's (FMS) second-quarter revenues suffer due to divestures. However, the company???s transformational plans continue to benefit its operating income.
Ecolab (ECL) Q2 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Ecolab's (ECL) robust performance across the majority of its segments drives its second-quarter sales amid business challenges.
Baxter's (BAX) Helion Surgical System Debuts in Thailand
by Zacks Equity Research
Baxter (BAX) launches the Helion Integrated Surgical System in Thailand, aiming to streamline operating room efficiency and enhance surgical team connectivity with cutting-edge technology.
Earnings Estimates Moving Higher for Universal Health Services (UHS): Time to Buy?
by Zacks Equity Research
Universal Health Services (UHS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Here's Why Universal Health Services (UHS) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Bet on These 5 Top-Ranked Value Stocks With Discounted PEG
by Urmimala Biswas
Invest in some top value stocks such as Hilton Grand Vacations (HGV), Tenet Healthcare (THC), Universal Health Services (UHS), Popular, Inc. (BPOP) and B2Gold Corp (BTG) that fit our screening criteria.
Avantor's (AVTR) Q2 Earnings Beat, Operating Margin Declines
by Zacks Equity Research
Avantor's (AVTR) revenues decline in the second quarter with new segmental changes. Bioprocessing orders decline. Operating margin contracts.
Revvity (RVTY) Q2 Earnings Beat Estimates, Guidance Revised
by Zacks Equity Research
Revvity's (RVTY) second-quarter results showcase a decline in life sciences segmental revenues.
Universal Health Services (UHS) Is Up 18.18% in One Week: What You Should Know
by Zacks Equity Research
Does Universal Health Services (UHS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Three Reasons to Retain Avanos (AVNS) Stock in Your Portfolio
by Zacks Equity Research
Avanos' (AVNS) strong product line and focus on R&D raise optimism about the stock.
DexCom's (DXCM) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
DexCom's (DXCM) second-quarter 2024 earnings surpass expectations while revenues fall short. The Sensor segment and CGM system expansion drive growth. Shares fall.
Hologic (HOLX) Buys Endomag to Boost Breast Cancer Solutions
by Zacks Equity Research
Hologic (HOLX) acquires Endomag for $310M, enhancing its breast cancer surgery portfolio with innovative technologies like Magseed and Magtrace, aiming to improve patient care and outcomes globally.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Universal Health Services, Inc. (UHS) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Universal Health Services (UHS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why Fast-paced Mover Universal Health Services (UHS) Is a Great Choice for Value Investors
by Zacks Equity Research
Universal Health Services (UHS) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.